Valfix Revenue and Competitors

VALFIX Medical is an early-stage fast-moving start up company. VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery VALFIX technology is designed to eliminate Mitral Regurgitation (MR) in over 90% of severe MR patients VALFIX is creating a solution that is the closest to the surgical standard in trans-catheter mitral valve repair and replacement The Need/Opportunity: Mitral regurgitation (MR) is one of the most prevalent and disabling heart conditions worldwide. Currently, the standard treatment for severe MR is open heart surgery. Globally there are more than 15 million Mitral Regurgitation patients, 4.5 million are suffering from severe MR. Only 2% of the 4.5 million severe MR patients undergo open heart surgery. The remaining 98% are sent home with drug therapy alone, resulting in nearly 50% of them dying within 2 years. The current available treatments for MR patients with heart failure are limited. Surgical repair and replacement are controversial, and new treatments are insufficient. ——- To learn more about VALFIX Medical visit our website at www.valfixmed.com or contact us directly at info@valfixmed.com